BIT Capital GmbH Buys 130,623 Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS)

Key Points

• BIT Capital GmbH increased its stake in COMPASS Pathways PLC by 112.9% during the first quarter, owning 246,320 shares worth approximately $704,000.
• Analysts have a mixed outlook on COMPASS Pathways, with a current average rating of "Moderate Buy" and price targets ranging from $6.00 to $45.00.
• COMPASS Pathways reported a loss of ($0.38) EPS for the last quarter, missing analyst estimates, while facing an anticipated full-year EPS of ($2.33).

BIT Capital GmbH grew its stake in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 112.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 246,320 shares of the company's stock after acquiring an additional 130,623 shares during the quarter. BIT Capital GmbH owned 0.27% of COMPASS Pathways worth $704,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. ARK Investment Management LLC boosted its position in COMPASS Pathways by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock worth $5,162,000 after acquiring an additional 68,601 shares during the last quarter. Cerity Partners LLC acquired a new position in COMPASS Pathways during the 1st quarter worth approximately $29,000. Alps Advisors Inc. boosted its position in COMPASS Pathways by 19.7% during the 1st quarter. Alps Advisors Inc. now owns 66,231 shares of the company's stock worth $189,000 after acquiring an additional 10,899 shares during the last quarter. Flagship Harbor Advisors LLC boosted its position in COMPASS Pathways by 27.7% during the 1st quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after acquiring an additional 3,134 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after acquiring an additional 5,003 shares during the last quarter. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Stock Performance

CMPS stock traded up $0.02 during trading hours on Tuesday, hitting $4.62. 376,533 shares of the stock were exchanged, compared to its average volume of 1,837,707. The company has a 50-day simple moving average of $4.00 and a two-hundred day simple moving average of $3.81. The firm has a market capitalization of $442.76 million, a P/E ratio of -2.50 and a beta of 2.17. COMPASS Pathways PLC Sponsored ADR has a 12 month low of $2.25 and a 12 month high of $8.54. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, analysts forecast that COMPASS Pathways PLC Sponsored ADR will post -2.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CMPS has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $12.00 price objective on shares of COMPASS Pathways in a report on Tuesday, May 27th. Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 price objective on shares of COMPASS Pathways in a report on Friday. HC Wainwright cut their price objective on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday. Finally, Evercore ISI reissued an "in-line" rating and issued a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $16.29.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.